BR112013001088A2 - "derivados substituídos como inibidores a quinase de imidazoquinolina" - Google Patents

"derivados substituídos como inibidores a quinase de imidazoquinolina"

Info

Publication number
BR112013001088A2
BR112013001088A2 BR112013001088A BR112013001088A BR112013001088A2 BR 112013001088 A2 BR112013001088 A2 BR 112013001088A2 BR 112013001088 A BR112013001088 A BR 112013001088A BR 112013001088 A BR112013001088 A BR 112013001088A BR 112013001088 A2 BR112013001088 A2 BR 112013001088A2
Authority
BR
Brazil
Prior art keywords
imidazoquinoline
kinase inhibitors
substituted derivatives
diseases
compounds
Prior art date
Application number
BR112013001088A
Other languages
English (en)
Inventor
Bichismita Sahu
Nishigandha Naik
Rajiv Sharma
Robert Zahler
Sanjay Kumar
Veena R Agarwal
Original Assignee
Piramal Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Entpr Ltd filed Critical Piramal Entpr Ltd
Publication of BR112013001088A2 publication Critical patent/BR112013001088A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

derivados substituídos como inibidores a quinase de imidazoquinolina. a presente invenção relaciona-se com imidazo substituído [4,5-c] quinolina derivados, os compostos de fórmula (i), em que r1, r2, r3, r4, r5, r6 e r7 são como definido na especificação, os processos para a sua preparação, composições farmacêuticos que compreendem os compostos de fórmula (i), e a sua utilização no tratamento de doenças ou distúrbios mediados por uma ou mais quinases, doenças ou desordens proliferativas em particular, tais como o cancro. estes compostos podem também ser usados no tratamento de doenças inflamatórias e de doenças relacionadas com a angiogénese.
BR112013001088A 2010-07-16 2011-07-15 "derivados substituídos como inibidores a quinase de imidazoquinolina" BR112013001088A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36492710P 2010-07-16 2010-07-16
PCT/IB2011/053161 WO2012007926A1 (en) 2010-07-16 2011-07-15 Substituted imidazoquinoline derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112013001088A2 true BR112013001088A2 (pt) 2016-05-24

Family

ID=44509505

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013001088A BR112013001088A2 (pt) 2010-07-16 2011-07-15 "derivados substituídos como inibidores a quinase de imidazoquinolina"

Country Status (14)

Country Link
US (1) US9062046B2 (pt)
EP (1) EP2593450A1 (pt)
JP (1) JP5750158B2 (pt)
KR (1) KR20130043198A (pt)
CN (1) CN103108873A (pt)
AR (1) AR084706A1 (pt)
AU (1) AU2011277935B2 (pt)
BR (1) BR112013001088A2 (pt)
CA (1) CA2805608A1 (pt)
MX (1) MX2013000617A (pt)
NZ (1) NZ607060A (pt)
RU (1) RU2013106427A (pt)
TW (1) TW201204725A (pt)
WO (1) WO2012007926A1 (pt)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014141118A1 (en) 2013-03-14 2014-09-18 Piramal Enterprises Limited Imidazo[4,5-c]quinoline derivatives and uses thereof
WO2014177915A1 (en) 2013-05-01 2014-11-06 Piramal Enterprises Limited Cancer combination therapy using imidazo[4,5-c]quinoline derivatives
US9227969B2 (en) 2013-08-14 2016-01-05 Novartis Ag Compounds and compositions as inhibitors of MEK
WO2015049629A1 (en) * 2013-10-01 2015-04-09 Piramal Enterprises Limited Imidazoquinoline compounds as bromodomain inhibitors
BR112016010716A8 (pt) 2013-11-13 2020-04-22 Novartis Ag dose de reforço imunológico, baixa, de um inibidor de mtor, seu uso, e adjuvante de vacina
CA3225453A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
WO2015145369A1 (en) * 2014-03-27 2015-10-01 Piramal Enterprises Limited Process for the preparation of substituted imidazo[4,5-c]quinoline compounds, intermediates and polymorphs thereof
HUE054588T2 (hu) 2014-04-07 2021-09-28 Novartis Ag Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
JP2017528433A (ja) 2014-07-21 2017-09-28 ノバルティス アーゲー 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
CN112481283A (zh) 2014-07-21 2021-03-12 诺华股份有限公司 使用cd33嵌合抗原受体治疗癌症
WO2016012982A1 (en) * 2014-07-25 2016-01-28 Piramal Enterprises Limited Combination therapy for the treatment of resistant breast cancer
EP3174546B1 (en) 2014-07-31 2019-10-30 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
JP6919118B2 (ja) 2014-08-14 2021-08-18 ノバルティス アーゲー ＧＦＲα−４キメラ抗原受容体を用いる癌の治療
MY189028A (en) 2014-08-19 2022-01-20 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
AU2015317608B2 (en) 2014-09-17 2021-03-11 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CA2963935A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
WO2016141296A1 (en) * 2015-03-04 2016-09-09 Dana-Farber Caner Institute, Inc. Tricyclic kinase inhibitors of melk and methods of use
EP3280795B1 (en) 2015-04-07 2021-03-24 Novartis AG Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
ES2948133T3 (es) 2015-04-17 2023-08-31 Novartis Ag Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
WO2016172583A1 (en) 2015-04-23 2016-10-27 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
ES2782113T3 (es) * 2015-07-11 2020-09-10 Advenchen Pharmaceuticals Llc Compuestos de quinolina fusionados como inhibidores de PI3K/mTor
CN109641947B (zh) 2016-07-20 2023-04-14 犹他大学研究基金会 Cd229 car t细胞及其使用方法
TW202340473A (zh) 2016-10-07 2023-10-16 瑞士商諾華公司 利用嵌合抗原受體之癌症治療
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CN111511361A (zh) * 2017-12-20 2020-08-07 安杰斯制药公司 作为多激酶抑制剂的胺基碳酸盐及尿素化合物
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
BR112020023040A2 (pt) * 2018-05-11 2021-02-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services compostos de quinolina e sua preparação e uso como agentes antimaláricos
SG11202012447YA (en) 2018-06-15 2021-01-28 Navitor Pharm Inc Rapamycin analogs and uses thereof
IL293549A (en) 2019-12-05 2022-08-01 Anakuria Therapeutics Inc Rapamycin analogs and their uses
US11530218B2 (en) 2020-01-20 2022-12-20 Incyte Corporation Spiro compounds as inhibitors of KRAS
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
WO2022047093A1 (en) 2020-08-28 2022-03-03 Incyte Corporation Vinyl imidazole compounds as inhibitors of kras
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
EP3992191A1 (en) 2020-11-03 2022-05-04 Deutsches Krebsforschungszentrum Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5011828A (en) * 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
BR0312752A (pt) * 2002-07-10 2005-04-26 Applied Research Systems Derivados de benzeno fundido de azolidinona-vinil
JP4908210B2 (ja) * 2003-07-28 2012-04-04 メルク セローノ ソシエテ アノニム Ｐｉ３キナーゼ阻害剤として使用するための２−イミノ−４−（チオ）オキソ−５−ポリシクロビニルアゾリン類
AR046845A1 (es) * 2003-11-21 2005-12-28 Novartis Ag Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas
RU2006121646A (ru) * 2003-11-21 2008-01-10 Новартис АГ (CH) Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
MXPA06014798A (es) * 2004-06-17 2007-06-22 Wyeth Corp Antagonistas del receptor de hormona para liberar gonadotropina.
WO2006029115A2 (en) * 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1h imidazo ring systems and methods
BRPI0515645A (pt) * 2004-09-07 2008-03-04 Orphan Medical Inc métodos terapêuticos, composições, compostos e usos de compostos
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CN101277933A (zh) * 2005-09-29 2008-10-01 惠氏公司 取代丙胺衍生物和其使用方法
WO2007075468A1 (en) * 2005-12-16 2007-07-05 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines, imidazonaphthyridines, and imidazopyridines, compositions, and methods
JP2010537998A (ja) * 2007-08-27 2010-12-09 ワイス・エルエルシー イミダゾピリジン類似体、およびＷｎｔ−βカテニン細胞メッセージ伝達系のアゴニストとしてのその使用

Also Published As

Publication number Publication date
MX2013000617A (es) 2013-06-13
KR20130043198A (ko) 2013-04-29
NZ607060A (en) 2015-02-27
WO2012007926A1 (en) 2012-01-19
US9062046B2 (en) 2015-06-23
JP2013535446A (ja) 2013-09-12
CN103108873A (zh) 2013-05-15
EP2593450A1 (en) 2013-05-22
US20130116248A1 (en) 2013-05-09
JP5750158B2 (ja) 2015-07-15
CA2805608A1 (en) 2012-01-19
AU2011277935A1 (en) 2013-03-07
RU2013106427A (ru) 2014-08-27
TW201204725A (en) 2012-02-01
AU2011277935B2 (en) 2015-01-22
AR084706A1 (es) 2013-06-05

Similar Documents

Publication Publication Date Title
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
BR112015026721A2 (pt) derivados de 3-(2-aminopirimidin-4-il)-5-(3-hidroxipropinil)-1h-pirrolo[2,3-c]piridina como inibidores de nik para o tratamento de câncer
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112014022000A8 (pt) compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende
BR112012012906A2 (pt) triazolopiridinas
BR112012017269A2 (pt) compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
BR112013003864A2 (pt) compostos de pirrolpirimidina e usos dos mesmos
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
BR112014026703A2 (pt) inibidores de dna-pk
IN2014MN01754A (pt)
BR112014033055A8 (pt) Inibidores seletivos de delta pi3k
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
EA201890650A1 (ru) ПРОИЗВОДНЫЕ 8-[6-[3-(АМИНО)ПРОПОКСИ]-3-ПИРИДИЛ]-1-ИЗОПРОПИЛ-ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА В КАЧЕСТВЕ СЕЛЕКТИВНЫХ МОДУЛЯТОРОВ КИНАЗЫ МУТАЦИИ АТАКСИИ-ТЕЛЕАНГИЭКТАЗИИ (ATM) ДЛЯ ЛЕЧЕНИЯ РАКА
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
PH12018500957A1 (en) Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer
EA201291098A1 (ru) Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ
GB201104267D0 (en) Pyrrolopyridineamino derivatives
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112012019765A2 (pt) composto, e, uso de um composto.
BR112012022650A2 (pt) derivados de imidazo [1,2-a]pirazina e seu uso como inibidores de pde10
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
BR112014012056A8 (pt) compostos farmacêuticos
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
BR112016005914A2 (pt) derivados de 1-(4-pirimidinil)-1h-pirrolo[3,2-c]piridina como inibidores de nik

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4A ANUIDADE

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2378 DE 02-08-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.